Thursday, 26 April 2012

Rodman & Renshaw Says Neptune Is Set To Outperform - $7 Target

Neptune Technologies & Bioressources
Basic Shares: 48.2 million
Fully Diluted: 53.9 million


Elemer Piros, Ph.D, Senior Biotechnology Analyst for Rodman & Renshaw has placed a price target of $7 on Neptune Technologies and Bioressources and expects it to outperform. This is a significant vote of confidence for the company as Rodman & Renshaw is widely recognized in the United States as a leader in the Life Science/Healthcare sector. Since 2003 Rodman has completed over 230 transactions and raised over $3.7 billion for healthcare companies.

The biotech sector has been heating up in the United States and the excitement is beginning to spill over into Canada.

As of the writing of this NEPT on the Nasdaq and NTB on the TSX has traded almost half a million shares and the price has jumped $0.26.